ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Northwell Health’s Clifford S. Deutschman recognized with Shock Society’s Scientific Achievement Award

The Scientific Achievement Award, which recognizes lifetime achievements in the field of shock research, was presented to Dr. Deutschman for his work with sepsis and inflammation

Sepsis is a life-threatening condition that arises when the body’s response to an infection spirals out of control, damaging the body's own tissues potentially leading to organ failure and death. Currently, there is no single standard of care for this often-fatal condition. For his dedication to sepsis research and discovery of new therapies to treat inflammation, Clifford S. Deutschman, MD, vice chair of research in the Department of Pediatrics at Northwell Health’s Cohen Children’s Medical Center and professor in the Institute of Molecular Medicine at Northwell’s Feinstein Institutes for Medical Research, has been awarded the Scientific Achievement Award at the 48th Annual Conference on Shock on June 3 in Boston, MA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707233286/en/

Dr. Lauren Moffatt, chair of the awards and honors committee at the Shock Society, presents the award to Dr. Cliff Deutschman. (Credit: Feinstein Institutes).

Dr. Lauren Moffatt, chair of the awards and honors committee at the Shock Society, presents the award to Dr. Cliff Deutschman. (Credit: Feinstein Institutes).

Dr. Deutschman has committed this career to critical care medicine, with an international reputation for his research on sepsis and shock. His work spans trying to better understand molecular mechanisms of sepsis-induced organ dysfunction to refining the clinical definitions of sepsis itself. His research investigates how sepsis disrupts endocrine, neural and cellular functions, focusing particularly on mitochondrial dysfunction and altered signal transmission in key organs like the heart, lung, liver and kidneys. He also studies the initiation of chronic inflammation by the central nervous system.

“There are more than 11 million sepsis-related deaths each year, and for more than four decades I have been focused on how to better understand this complex and all-too-often fatal disorder. I am honored to be recognized by my Shock Society colleagues with the Scientific Achievement Award,” said Dr. Deutschman. “But research is performed by teams, so this honor really belongs to the many individuals who have contributed to our ongoing efforts at unraveling the complexities of sepsis. I look forward to future investigations and the potential to use what we learn to improve the care of patients with sepsis.”

Dr. Deutschman, a leader in critical care medicine, is a Master of Critical Care Medicine (MCCM) — a distinction held by only about 100 individuals worldwide. He served as president of the Society of Critical Care Medicine and the American Society of Critical Care Anesthesiologists. His contributions to the field extend to editorial leadership as the scientific editor of Critical Care Medicine and permanent membership on the National Institutes of Health’s Surgery, Anesthesia and Trauma Study Section, a group that reviews applications examining the complementary disciplines of surgery and anesthesiology. Among his numerous awards and honors is the Lifetime Achievement Award from the Society of Critical Care Anesthesiologists.

He has also co-authored more than 160 peer-reviewed publications, and over 90 book chapters and editorials. He is the co-editor of three editions of the textbook, Evidence-Based Practice of Critical Care.

“Dr. Deutschman’ pioneering research into the how sepsis affects the body, particularly his work on mitochondrial dysfunction, the central nervous system’s role in inflammation, and the refinement of sepsis definitions, has significantly advanced our understanding of this complex and life-threatening condition,” said Charles Schleien, MD, MBA, senior vice president and chair of pediatric services at Northwell Health and the Philip Lanzkowsky Chair and Professor of Pediatrics and Anesthesiology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. “His recognition with the Shock Society’s Scientific Achievement award is well-deserved.”

The Shock Society was founded in 1978 by a group of dedicated clinicians and researchers whose mission is to improve the care of victims of trauma, shock and sepsis by promoting clinically relevant research, providing a multidisciplinary forum to integrate and disseminate new knowledge, and promoting the education and mentoring of the next generation of investigators in the field.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  234.03
+0.15 (0.06%)
AAPL  283.32
+0.22 (0.08%)
AMD  219.76
+0.00 (0.00%)
BAC  53.24
+0.00 (0.00%)
GOOG  315.12
+0.00 (0.00%)
META  641.15
+0.28 (0.04%)
MSFT  486.74
+0.00 (0.00%)
NVDA  180.00
+0.08 (0.04%)
ORCL  200.94
+0.00 (0.00%)
TSLA  430.22
+0.08 (0.02%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.